Publication Date:
1991-11-01
Description:
The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Golumbek, P T -- Lazenby, A J -- Levitsky, H I -- Jaffee, L M -- Karasuyama, H -- Baker, M -- Pardoll, D M -- New York, N.Y. -- Science. 1991 Nov 1;254(5032):713-6.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Medicine, Johns Hopkins University, Baltimore, MD 21205.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/1948050" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Carcinoma, Renal Cell/genetics/immunology/pathology/*therapy
;
Cell Division
;
Cell Line
;
*Immunotherapy
;
Interleukin-4/*genetics/secretion
;
Kidney Neoplasms/genetics/immunology/pathology/*therapy
;
Lymphocyte Depletion
;
Mice
;
Mice, Inbred BALB C
;
Mice, SCID
;
Neoplasm Transplantation
;
*Protein Engineering
;
T-Lymphocyte Subsets/immunology
;
Transfection
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
